Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Citius Pharmaceuticals Inc (CTXR) vs iShares MSCI Taiwan ETF (EWT) Price & Performance

Citius Pharmaceuticals IncTrade
iShares MSCI Taiwan ETFTrade

Price performance (Past 24H)

Key statistics

Citius Pharmaceuticals Inc vs iShares MSCI Taiwan ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.72 (market cap $20.01M), while iShares MSCI Taiwan ETF trades at $106.27. The key difference: iShares MSCI Taiwan ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

CTXREWT
Market Cap
$20.01M
Sector
HealthBroad Market / Factor
52-Week High
$1.82$111.53
52-Week Low
$0.48$58.05
Enterprise Value
$16.23M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Citius Pharmaceuticals Inc

CTXR is trading at $0.7126, up 5.26% today, with strong technical momentum showing bullish moving average signals. The company shows significant revenue growth potential with LYMPHIR commercialization expanding, though currently operates at substantial losses with a -823% net income margin. Analyst sentiment remains overwhelmingly positive with 83% buy ratings, reflecting optimism about the oncology pipeline and recent commercial progress.

The investment case hinges on successful LYMPHIR commercialization offsetting current losses, with strong institutional support providing runway. Key risks include execution challenges in scaling operations and the capital-intensive nature of biopharmaceutical development. The stock presents high-risk, high-reward potential for investors comfortable with clinical-stage biotech volatility.

iShares MSCI Taiwan ETF

EWT, the iShares MSCI Taiwan ETF, trades at $106.50, up 4.23% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF is heavily concentrated in Taiwan's technology sector, particularly semiconductors like TSMC, benefiting from AI-driven demand. Recent news highlights strong performance in 2026, with gains near 50%, though foreign outflows in July indicate some rotation away from AI-heavy markets.

Outlook remains positive due to Taiwan's critical role in AI semiconductor supply chains, but risks include geopolitical tensions with China, market concentration, and volatility from foreign capital flows. Analyst sentiment is generally bullish, citing growth-adjusted valuations and resilient fundamentals.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.

Read more on CTXR

About iShares MSCI Taiwan ETF

EWT tracks the MSCI Taiwan 25/50 Index, providing targeted exposure to large and mid-cap companies in Taiwan. It is heavily concentrated in the information technology sector, serving as a liquid instrument for investors seeking a single-country view of Taiwan's export-oriented and tech-driven economy.

Read more on EWT